AI medical imaging analysis company AIDOT (CEO: Jaehun Jung) announced that it has successfully obtained medical device registration in Vietnam for its AI-powered urinary stone detection solution, “URO dot AI,” marking a significant step toward expanding its presence in the Southeast Asian market.

URO dot AI has been registered as a Class B medical device in Vietnam.

The solution is designed to analyze non-contrast abdominal CT scans by reconstructing 2D images into 3D, enabling detailed visualization of anatomical structures. It can also identify the location of urinary stones—whether in the kidney, ureter, or bladder—supporting more precise clinical assessment.

Notably, the system is capable of detecting small stones measuring less than 4 mm. It also differentiates between stones and similar structures, such as vascular plaques, thereby improving overall diagnostic accuracy.

Urinary stones are a highly recurrent condition that can cause severe pain, making rapid and accurate diagnosis essential. AIDOT expects that URO dot AI will reduce the reading burden on clinicians by providing intuitive and quantifiable information, while also improving efficiency across the diagnostic process, including pre- and post-treatment monitoring.

Leveraging these strengths, the company anticipates that URO dot AI will serve as an effective clinical decision-support tool across a wide range of healthcare settings in Vietnam and other Southeast Asian markets, including regions beyond major metropolitan areas.

With this registration, AIDOT plans to actively expand the supply and adoption of URO dot AI within the local market.

An AIDOT representative stated, “This registration in Vietnam is meaningful as it establishes a foundation for URO dot AI’s entry into the local market. We will continue to enhance its clinical utility and real-world applicability as we expand into global markets.”

Korea Economic TV / 2026-03-17 / Yang Jaejun, Deputy Managing Editor